LC3‑Ⅱ/LC3‑Ⅰ Cancer Research Results

LC3‑Ⅱ/LC3‑Ⅰ, ratio of LC3‑Ⅱ/LC3‑Ⅰ: Click to Expand ⟱
Source:
Type: marker
The ratio of LC3-II to LC3-I is often used as a marker for autophagy, a cellular process in which cells recycle their damaged or dysfunctional components. In cancer, autophagy can play a complex role, and the LC3-II/LC3-I ratio can be used to assess autophagic activity.
Many cancers, have an increased LC3-II/LC3-I ratio indicating enhanced autophagy, which can support tumor cell survival, especially under stress conditions (e.g., nutrient deprivation, hypoxia). This is often associated with poor prognosis and treatment resistance.
Cell Survival: Increased autophagy, as indicated by a higher LC3-II/LC3-I ratio, can help cancer cells survive in adverse conditions, contributing to tumor growth and metastasis.
Therapeutic Resistance: Elevated autophagy can lead to resistance against chemotherapy and targeted therapies, as cancer cells may utilize autophagy to survive treatment-induced stress.
Metabolic Adaptation: Autophagy allows cancer cells to adapt to metabolic stress by recycling cellular components, which can support continued proliferation and survival.
Scientific Papers found: Click to Expand⟱
1377- BBR,    Berberine inhibits autophagy and promotes apoptosis of fibroblast-like synovial cells from rheumatoid arthritis patients through the ROS/mTOR signaling pathway
- in-vitro, Arthritis, NA
Apoptosis↑, MMP↓, Bax:Bcl2↑, LC3‑Ⅱ/LC3‑Ⅰ↓, p62↑, *ROS↓,
1656- FA,    Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
- Review, Var, NA
tyrosinase↓, CK2↓, TumCP↓, TumCMig↓, FGF↓, FGFR1↓, PI3K↓, Akt↓, VEGF↓, FGFR1↓, FGFR2↓, PDGF↓, ALAT↓, AST↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, BAX↓, Bcl-2↓, MMP2↓, MMP9↓, P53↑, PARP↑, PUMA↑, NOXA↑, Casp3↑, Casp9↑, TIMP1↑, lipid-P↑, mtDam↑, EMT↓, Vim↓, E-cadherin↓, p‑STAT3↓, COX2↓, CDC25↓, RadioS↑, ROS↑, DNAdam↑, γH2AX↑, PTEN↑, LC3II↓, Beclin-1↓, SOD↓, Catalase↓, GPx↓, Fas↑, *BioAv↓, cMyc↓, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   GPx↓, 1,   lipid-P↑, 1,   ROS↑, 1,   SOD↓, 1,  

Mitochondria & Bioenergetics ⓘ

CDC25↓, 1,   FGFR1↓, 2,   MMP↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   cMyc↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAX↓, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,   CK2↓, 1,   Fas↑, 1,   NOXA↑, 1,   PUMA↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,   Beclin-1↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↓, 2,   LC3II↓, 1,   p62↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 1,   PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   FGF↓, 1,   FGFR2↓, 1,   PI3K↓, 1,   PTEN↑, 1,   p‑STAT3↓, 1,   tyrosinase↓, 1,  

Migration ⓘ

E-cadherin↓, 1,   MMP2↓, 1,   MMP9↓, 1,   PDGF↓, 1,   TIMP1↑, 1,   TumCMig↓, 1,   TumCP↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

RadioS↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,  
Total Targets: 55

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  
Total Targets: 2

Scientific Paper Hit Count for: LC3‑Ⅱ/LC3‑Ⅰ, ratio of LC3‑Ⅱ/LC3‑Ⅰ
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:685  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page